LLY

1,071.53

+0.34%↑

JNJ

205.37

-0.98%↓

ABBV

229.2

+0.63%↑

UNH

324.87

+0.03%↑

AZN

92.08

+0.63%↑

LLY

1,071.53

+0.34%↑

JNJ

205.37

-0.98%↓

ABBV

229.2

+0.63%↑

UNH

324.87

+0.03%↑

AZN

92.08

+0.63%↑

LLY

1,071.53

+0.34%↑

JNJ

205.37

-0.98%↓

ABBV

229.2

+0.63%↑

UNH

324.87

+0.03%↑

AZN

92.08

+0.63%↑

LLY

1,071.53

+0.34%↑

JNJ

205.37

-0.98%↓

ABBV

229.2

+0.63%↑

UNH

324.87

+0.03%↑

AZN

92.08

+0.63%↑

LLY

1,071.53

+0.34%↑

JNJ

205.37

-0.98%↓

ABBV

229.2

+0.63%↑

UNH

324.87

+0.03%↑

AZN

92.08

+0.63%↑

Strona główna・Stock List・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Open

SectorHealthcare

4.3 -3.37

Buy Sell

Overview

Share price change

24h

Current

Min

4.18

Max

4.46

Key metrics
By Trading Economics
Income	9.6M -162M
Sales	-14M 5.2M
EPS	-0.36
Profit margin	-3,135.324
Employees	800
EBITDA	6.4M -141M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+81.92% upside

Market Stats
By TradingEconomics
Market Cap	-186M 2.2B
Previous open	7.67
Previous close	4.3

News Sentiment

By Acuity

50%

166 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

4.15 / 4.75 Support & Resistance

Recursion Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 gru 2025, 23:54 UTC

Major Market Movers

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22 gru 2025, 19:08 UTC

Acquisitions, Mergers, Takeovers

Correction to Alphabet to Buy Intersect Article

22 gru 2025, 17:21 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22 gru 2025, 16:46 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Buy Intersect for $4.75 Billion in Cash

22 gru 2025, 23:50 UTC

Market Talk

Nikkei May Decline as Yen Rebounds -- Market Talk

22 gru 2025, 23:42 UTC

Market Talk

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22 gru 2025, 22:31 UTC

Earnings

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22 gru 2025, 22:31 UTC

Earnings

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22 gru 2025, 22:30 UTC

Earnings

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 gru 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

22 gru 2025, 21:37 UTC

Acquisitions, Mergers, Takeovers

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22 gru 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22 gru 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Capricorn to Acquire Prospective Package From Tempest Minerals

22 gru 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22 gru 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22 gru 2025, 20:52 UTC

Acquisitions, Mergers, Takeovers

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22 gru 2025, 20:09 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22 gru 2025, 19:56 UTC

Market Talk

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22 gru 2025, 19:49 UTC

Acquisitions, Mergers, Takeovers

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22 gru 2025, 19:23 UTC

Market Talk

Mexico's Inflation Seen Easing in Early December -- Market Talk

22 gru 2025, 19:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 gru 2025, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

22 gru 2025, 19:02 UTC

Market Talk

Precious Metals Climb to New Heights -- Market Talk

22 gru 2025, 18:45 UTC

Market Talk

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22 gru 2025, 18:30 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22 gru 2025, 18:23 UTC

Acquisitions, Mergers, Takeovers

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22 gru 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

22 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22 gru 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

81.92% upside

12 Months Forecast

Average 7.75 USD 81.92%

High 11 USD

Low 5 USD

Based on 6 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Recursion Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.15 / 4.75Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

166 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.